ANTH Stock Price, Chart, Stats & News

Anthera Pharmaceuticals, Inc.
Save
Anthera Pharmaceuticals, Inc. (ANTH) does not currently pay a dividend.
2,618
Market cap
–
Current P/E
–
Forward P/E
ANTH chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy).
Similar securities
Based on sector and market capitalization
Report issue





